Portal de Periódicos da CAPES

Clinical Applications of Iron Management in Hemodialysis Patients

1999; Wiley; Volume: 12; Issue: 4 Linguagem: Inglês

10.1046/j.1525-139x.1999.99032.x

1525-139X

Jeffrey S. Berns, Peter B. DeOreo,

Iron Metabolism and Disorders

Seminars in DialysisVolume 12, Issue 4 p. 249-256 Clinical Applications of Iron Management in Hemodialysis Patients Jeffrey S. Berns, Jeffrey S. Berns Department of Medicine and Division of Nephrology and Hypertension, Graduate Hospital, Philadelphia, Pennsylvania,Search for more papers by this authorPeter B. DeOreo, Peter B. DeOreo Division of Nephrology, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OhioSearch for more papers by this author Jeffrey S. Berns, Jeffrey S. Berns Department of Medicine and Division of Nephrology and Hypertension, Graduate Hospital, Philadelphia, Pennsylvania,Search for more papers by this authorPeter B. DeOreo, Peter B. DeOreo Division of Nephrology, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OhioSearch for more papers by this author First published: 05 January 2002 https://doi.org/10.1046/j.1525-139X.1999.99032.xCitations: 2 Jeffrey S. Berns MD Graduate Hospital, 19th and Lombard Streets, Pepper Pavilion, Suite 703, Philadelphia, PA 19146 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 1997 ESRD Core Indicators Project: The Management of Anemia in Adult In-Center Hemodialysis and Peritoneal Dialysis Patients: Supplemental Report 3. Baltimore, MD: Health Care Financing Administration, April 1998 2 Eschbach J, DeOreo P, Adamson J, Berns J, Biddle G, Comstock T, Jabs K, Lazarus J, Nissenson A, Stivelman J, Van Wyck D, Wish J: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(Suppl 3): S192 S240, 1997 3 U.S. Renal Data System (USRDS): USRDS 1996 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, April 1996 4 Ruggenenti P, Mecca G, Remuzzi G, Coen D: Are “routine” clinical and laboratory examinations of any help in the treatment of chronic hemodialysis patients? Am J Kidney Dis 10: 23 27, 1987 5 Sunder-Plassmann G & Hörl WH: Laboratory diagnosis of anaemia in dialysis patients: Use of common laboratory tests. Curr Opin Nephrol Hypertens 6: 566 569, 1997 6 Fishbane S, Trenkle J, Maesaka JK: Utilizing continuous quality improvement techniques in dialysis: Application to anemia management. Semin Dial 11: 38 44, 1998 7 MacDougall IC: Optimal iron management in patients receiving erythropoietin therapy. Semin Dial 11: 10 13, 1998 8 Drüeke TB, Bárány P, Cazzola M, Eschbach JW, Grützmacher P, Kaltwasser JP, MacDougall IC, Pippard MJ, Shaldon S, Van Wyck D: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 48: 1 8, 1997 9 Nissenson AR: Achieving target hematocrit in dialysis patients: New concepts in iron management. Am J Kidney Dis 30: 907 911, 1997 10 Hutchison F & Jones WJ: A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 29: 651 657, 1997 11 Rosenlöf K, Kivivuori SM, Grönhagen-Riska C, Teppo AM, Slimes MA: Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43: 249 255, 1995 12 Saltissi D, Sauvage D, Westhuyzen J: Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin Nephrol 49: 45 48, 1998 13 Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram MM: Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving recombinant human erythropoietin. Am J Kidney Dis 30: 912 922, 1997 14 Roe DJ, Harford AM, Zager PG, Wiltbank TH, Kirlin L, DellaValle AM, Van Wyck DB: Iron utilization after iron dextran administration for iron deficiency in patients with dialysis associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis 28: 855 860, 1996 15 Fishbane S, Galgano C, Langley Jr RC, Canfield W, Maesaka J: Reticulocyte hemoglobin content in the evaluation of iron status in hemodialysis patients. Kidney Int 52: 217 222, 1997 16 Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH: Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after I.V. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12: 1173 1181, 1997 17 Fishbane S, Goreja M, Maesaka JK: Hematocrit cycling in hemodialysis patients.[Abstract]J Am Soc Nephrol 8: 235A, 1997 18 Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7: 2654 2657, 1996 19 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53 61, 1996 20 Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921 1929, 1997 21 Churchill DN, Muirhead N, Goldstein M: Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 43: 184 188, 1995 22 Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27: 234 238, 1996 23 Ahsan N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single-center comparative study. J Am Soc Nephrol 9: 664 668, 1998 24 Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25: 433 439, 1995 25 Lim VS, Kirchner PT, Fangman J, Richmond J, DeGowin RL: The safety and efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 14: 496 506, 1989 26 Eschbach JW, Kelly MR, Haly R, Abels RI: Treatment of the anemia of progressive renal failure with recombinant erythropoietin. N Engl J Med 321: 158 163, 1989 27 Park L, Uhthoff T, Tierney M, Nadler S: Effect of an intravenous iron dextran regimen on iron stores, hemoglobin and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 31: 835 840, 1998 28 MacDougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled trial of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694 1699, 1996 29 Fishbane S, Goreja MAJ, Maesaka JK: Reduced nPCR patients with gastrointestinal side effects due to ferrous sulfate.[Abstract]J Am Soc Nephrol 9: 248A, 1998 30 Kooistra MP, Niemantsverdriet EC, Van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation, and aluminum. Nephrol Dial Transplant 13: 82 88, 1998 31 Dunea G, Swagel MA, Bodiwala U, Arruda JAL: Intradialytic oral iron therapy. Int J Artif Organs 17: 261 264, 1994 32 Fourtounas C, Koutsikos D, Dalamangas A, Kapetanaki A, Kostoglou M, Agrouannis B, Tzanatos H, Kopelias I, Bosliolis B: Supervised intradialytic oral iron administration during erythopoietin therapy.[Letter]Nephrol Dial Transplant 11: 1485 1486, 1996 33 Gupta A: Oral iron therapy in hemodialysis patients and the new NKF-DOQI clinical practice guidelines.[Letter]Am J Kidney Dis 31: 556 558, 1998 34 Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48: 34 40, 1997 35 Kotaki M, Uday K, Henriquez M, Blum S, Dave M: Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.[Letter]Clin Nephrol 48: 63 64, 1997 36 Ahluwalia N, Skikne BS, Savin V, Chonko A: Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 30: 532 541, 1997 37 Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28: 529 534, 1996 38 Collins A, Ebben J, Ma J, Xia H: IV iron dosing patterns and mortality.[Abstract]J Am Soc Nephrol 9: 205A, 1998 39 Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41 46, 1995 40 St. Peter WL, Lambrecht LJ, Macres M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28: 523 538, 1996 41 Auerbach M, Winchester J, Wahab A, Richards K, McGinley M, Hall F, Anderson J, Briefel G: A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 31: 81 86, 1998 42 Zanen AL, Adriaansen HJ, Van Bommel EFH, Posthuma R, DeJong GMTH: “Oversaturation” of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11: 820 824, 1996 43 Granolleras C, Zein A, Oulès R, Branger B, Fourcade J, Shaldon S: Continuous administration of intravenous iron during haemodialysis. Nephrol Dial Transplant 12: 1007 1008, 1997 44 Briglia A, Harrington F, Ellis P, Bednarz D, Magnusson M, Heyka R, Paganini EP: Differing intravenous iron dextran loading dosing and subsequent laboratory responses in chronic hemodialysis patients: Effect of total and pulse dosage amount.[Abstract]J Am Soc Nephrol 8: 187A, 1997 45 Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: An in vitro study. Am J Kidney Dis 26: 327 330, 1995 46 Rolla G, Bucca C, Brussino L: Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 93: 1074 1075, 1994 47 Newsom L, Erstad BL, Nakazato PZ, Daller JA: Falsely decreased total serum calcium concentration associated with iron dextran injection. Pharmacotherapy 15: 789 792, 1995 48 Patterson P & Allon M: Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis 32: 635 641, 1998 49 Bárány P, Filho JCD, Bergström J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565 568, 1997 50 Faich G & Strobos J: Sodium ferric gluconate complex in sucrose: Safer intravenous iuron therapy than iron dextran. Am J Kidney Dis 33: 464 470, 1999 51 Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33: 471 482, 1999 Citing Literature Volume12, Issue4August 1999Pages 249-256 ReferencesRelatedInformation